PRC2: A Promising Drug Target for Various Diseases (P19878)

Target Name: Polycomb Repressive Complex 2

NCBI ID: P19878

Polycomb Repressive Complex 2

Other Name(s): Polycomb Repressive Complex 2 (PRC2)/EED-EZH1 Complex | PRC2 | PRC2 Complex

PRC2: A Promising Drug Target for Various Diseases

Polycomb Repressive Complex 2 (PRC2) is a protein that plays a crucial role in cellular processes such as DNA replication, repair, and gene expression. Mutations in the PRC2 gene have been linked to various diseases, including cancer, neurodegenerative diseases, and developmental disorders . Therefore, PRC2 has emerged as a promising drug target for researchers to develop new treatments for these diseases.

The PRC2 complex is composed of several subunits, including Polycomb protein, Repressive Complex 2 chaperone protein, and phosphorylase. The interaction between these subunits enables PRC2 to efficiently repair and replicate DNA. The function of PRC2 mainly depends on its chaperone proteins, which can bind to the C-terminus of PRC2, thereby increasing the stability of PRC2. In addition, phosphorylase also plays a key role in the function of PRC2, as it is able to phosphorylate the putative GDP-binding site in PRC2, thereby enhancing its function.

Aberrant expression of PRC2 has contributed to a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, researchers have been exploring drug targets for PRC2. At present, research on PRC2 drug targets mainly focuses on two aspects: one is anti-tumor drugs, and the other is drugs for neurodegenerative diseases.

Research on anti-tumor drugs mainly focuses on inhibition strategies of PRC2. Many studies have shown that PRC2 inhibition strategies are positively correlated with tumor progression and invasive capabilities. Therefore, researchers are exploring anti-tumor drugs, including anti-tumor antibiotics, anti-tumor vaccines, and anti-tumor gene therapy. The goals of these drugs are to inhibit the function of PRC2, thereby preventing tumor progression and invasion.

Research on drugs for neurodegenerative diseases has mainly focused on modulation strategies of PRC2. Many studies have shown that abnormal expression of PRC2 is closely related to the occurrence and development of neurodegenerative diseases. Therefore, researchers are exploring the regulatory strategies of PRC2, including regulating the expression level of PRC2, regulating the phosphorylation modification of PRC2, and regulating the chaperone protein of PRC2. The goals of these drugs are to modulate the function of PRC2 and thereby alleviate neurodegenerative diseases.

Overall, PRC2 is a very promising drug target that has attracted widespread attention from academia and industry. Future research will continue to further explore the functions and drug targets of PRC2, providing new ideas and hope for the treatment of various diseases.

Protein Name: Polycomb Repressive Complex 2

The "Polycomb Repressive Complex 2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Polycomb Repressive Complex 2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets